Moderator's view: Higher serum bicarbonate in dialysis patients is protective

Nephrology Dialysis Transplantation

Volumn 31, Issue 8, 2016, Pages 1231-1234

  Kalantar Zadeh, Kamyar ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

Acetate; Acid concentrate; Death; Hemodialysis; Metabolic acidosis

Indexed keywords

BICARBONATE; PROTON; DIALYSIS FLUID;

ACID BASE BALANCE; ARTICLE; BICARBONATE BLOOD LEVEL; CAUSAL ATTRIBUTION; CHRONIC KIDNEY DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; METABOLIC ACIDOSIS; MORTALITY RISK; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; ACIDOSIS; BLOOD; CHEMICALLY INDUCED; FLUID THERAPY; KIDNEY FAILURE, CHRONIC;

ACIDOSIS; BICARBONATES; DIALYSIS SOLUTIONS; FLUID THERAPY; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 84982128285     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw258     Document Type: Article

References (17)

1. Misra M. Pro: Higher serum bicarbonate in dialysis patients is protective. Nephrol Dial Transplant 2016 (in press)
2. Chauveau P, Rigothier C, Combe C. Con: Higher serum bicarbonate in dialysis patients is protective. Nephrol Dial Transplant 2016 (in press)
3. Kalantar-Zadeh K, Rhee C, Sim JJ et al. Why cachexia kills: examining the causality of poor outcomes in wasting conditions. J Cachexia Sarcopenia Muscle 2013; 4: 89-94
4. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300
5. Miller JE, Molnar MZ, Kovesdy CP et al. Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis. Pharmacoepidemiol Drug Saf 2012; 21: 1232-1239
6. Streja E, Park J, Chan T-Y et al. Erythropoietin dose and mortality in hemodialysis patients: marginal structural modelling to examine causality. Int J Nephrol 2016; 2016: 6087134
7. Kalantar-Zadeh K. What is so bad about reverse epidemiology anyway? Semin Dial 2007; 20: 593-601
8. Kovesdy CP, Kalantar-Zadeh K. Observational studies versus randomized controlled trials: avenues to causal inference in nephrology. Adv Chronic Kidney Dis 2012; 19: 11-18
9. Kalantar-Zadeh K, Mehrotra R, Fouque D et al. Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. Semin Dial 2004; 17: 445-465
10. Kopple JD, Kalantar-Zadeh K, Mehrotra R. Risks of chronic metabolic acidosis in patients with chronic kidney disease. Kidney Int Suppl 2005; 95: S21-S27
11. Wu DY, Kilpatrick RD, Dadres S et al. Association between serum bicarbonate and death in hemodialysis patients: Is it better to be acidotic or alkalotic? Hemodial Int 2005; 9: 110
12. Wu DY, Shinaberger CS, Regidor DL et al. Association between serum bicarbonate and death in hemodialysis patients: Is it better to be acidotic or alkalotic? Clin J Am Soc Nephrol 2006; 1: 70-78
13. Vashistha T, Kalantar-Zadeh K, Molnar MZ et al. Dialysis modality and correction of uremic metabolic acidosis: relationship with all-cause and cause-specific mortality. Clin J Am Soc Nephrol 2013; 8: 254-264
14. Bommer J,LocatelliF, SatayathumS et al. Associationof predialysis serumbicarbonate levels with riskofmortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 661-671
15. Kalantar-Zadeh K, Cano NJ, Budde K et al. Diets and enteral supplements for improvingoutcomesinchronickidneydisease. NatRevNephrol2011;7:369-384
16. Kohn OF, Kjellstrand CM, Ing TS. Dual-concentrate bicarbonate-based hemodialysis: know your buffers. Artif Organs 2012; 36: 765-768
17. Desai N. Basics of base in hemodialysis solution: dialysate buffer production, delivery and decontamination. Indian J Nephrol 2015; 25: 189-193